In accordance with these findings, CD26hi/CD4+ T cells genetically engineered to express a CAR recognizing mesothelin, an antigen overexpressed in mesothelioma, displayed an outstanding capacity to traffic to, survive in, and regress solid tumors in NSG xenograft mesothelioma models. This evidence concerns the gene CD4 and mesothelioma.